Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 374

Similar articles for PubMed (Select 23410540)

1.

Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population.

Shelton R, Eftychiou C, Somers K, Liu A, Burton-Wood N, Anderson M, Makri L, Blaxill J, McLenachan J, Wheatcroft S, Greenwood J, Blackman D.

EuroIntervention. 2013 May 20;9(1):118-24. doi: 10.4244/EIJV9I1A17.

2.

Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.

Ndrepepa G, Neumann FJ, Deliargyris EN, Mehran R, Mehilli J, Ferenc M, Schulz S, Schömig A, Kastrati A, Stone GW.

Circ Cardiovasc Interv. 2012 Oct;5(5):705-12. doi: 10.1161/CIRCINTERVENTIONS.112.972869. Epub 2012 Oct 9.

3.

Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty.

Shah A, Feldman DN.

Vasc Health Risk Manag. 2012;8:115-23. doi: 10.2147/VHRM.S23491. Epub 2012 Feb 27. Review.

4.

Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice.

Showkathali R, Davies JR, Parker M, Taggu W, Tang KH, Clesham GJ, Gamma RA, Sayer JW, Aggarwal RK, Kelly PA.

Cardiovasc Revasc Med. 2013 Sep-Oct;14(5):289-93. doi: 10.1016/j.carrev.2013.07.006. Epub 2013 Aug 22.

PMID:
23972537
5.

Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.

Hibbert B, MacDougall A, Labinaz M, O'Brien ER, So DY, Dick A, Glover C, Froeschl M, Marquis JF, Wells GA, Blondeau M, Le May MR.

Circ Cardiovasc Interv. 2012 Dec;5(6):805-12. doi: 10.1161/CIRCINTERVENTIONS.112.968966. Epub 2012 Nov 13.

6.

Bivalirudin during primary PCI in acute myocardial infarction.

Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators.

N Engl J Med. 2008 May 22;358(21):2218-30. doi: 10.1056/NEJMoa0708191.

7.

Two hour bivalirudin infusion after PCI for ST elevation myocardial infarction.

Anderson PR, Gogo PB, Ahmed B, Straight F, Terrien EF, Watkins MW, El Gharib N, Dauerman HL.

J Thromb Thrombolysis. 2011 May;31(4):401-6. doi: 10.1007/s11239-010-0528-7.

PMID:
21107655
8.
9.

Bivalirudin therapy is associated with improved clinical and economic outcomes in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: results from an observational database.

Pinto DS, Ogbonnaya A, Sherman SA, Tung P, Normand SL.

Circ Cardiovasc Qual Outcomes. 2012 Jan;5(1):52-61. doi: 10.1161/CIRCOUTCOMES.111.961938. Epub 2012 Jan 10.

10.

Bleeding complications with regional adaptation of a prolonged bivalirudin regimen for ST-elevation acute myocardial infarction.

Mueller E, Prabhu W, Desarno M, Sundaran P, Dauerman H.

Am J Cardiol. 2012 Dec 1;110(11):1607-12. doi: 10.1016/j.amjcard.2012.07.024. Epub 2012 Aug 15.

PMID:
22901969
11.

Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.

Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, Chen S, Jiang T, Yang P, Chen J, Jiang D, Jing Q, Liang Z, Liu H, Zhao X, Li J, Li Y, Xu B, Stone GW; BRIGHT Investigators.

JAMA. 2015 Apr 7;313(13):1336-46. doi: 10.1001/jama.2015.2323.

PMID:
25775052
12.

Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.

Olchanski N, Slawsky KA, Plent S, Kado C, Cyr PL.

Hosp Pract (1995). 2010 Nov;38(4):138-46. doi: 10.3810/hp.2010.11.351.

PMID:
21068538
13.

Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).

Stone GW, Clayton T, Deliargyris EN, Prats J, Mehran R, Pocock SJ.

J Am Coll Cardiol. 2014 Jan 7-14;63(1):15-20. doi: 10.1016/j.jacc.2013.09.027. Epub 2013 Oct 16.

14.

Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy.

Wöhrle J, Merkle N, Kunze M, Cristea E, Mehran R, Rottbauer W, Stone GW.

Catheter Cardiovasc Interv. 2012 Jun 1;79(7):1083-9. doi: 10.1002/ccd.23179. Epub 2011 Dec 7.

PMID:
22162175
15.

Bivalirudin started during emergency transport for primary PCI.

Steg PG, van 't Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, Ten Berg J, Van Grunsven P, Eggink GJ, Nibbe L, Zeymer U, Campo dell' Orto M, Nef H, Steinmetz J, Soulat L, Huber K, Deliargyris EN, Bernstein D, Schuette D, Prats J, Clayton T, Pocock S, Hamon M, Goldstein P; EUROMAX Investigators.

N Engl J Med. 2013 Dec 5;369(23):2207-17. doi: 10.1056/NEJMoa1311096. Epub 2013 Oct 30.

16.

Safety of bivalirudin in percutaneous coronary intervention following thrombolytic therapy.

Sardi GL, Lindsay J, Waksman R.

Catheter Cardiovasc Interv. 2013 Oct 1;82(4):614-20. doi: 10.1002/ccd.24478. Epub 2013 Jul 4.

PMID:
22581418
17.

Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.

Nairooz R, Sardar P, Amin H, Swaminathan RV, Kim LK, Chatterjee S, Feldman DN.

Am J Cardiol. 2014 Jul 15;114(2):250-9. doi: 10.1016/j.amjcard.2014.04.033. Epub 2014 May 2. Review.

PMID:
24890986
18.

The bivalirudin paradox: high evidence, low use.

De Servi S, Mariani G, Mariani M, D'Urbano M.

J Cardiovasc Med (Hagerstown). 2013 May;14(5):334-41. doi: 10.2459/JCM.0b013e32835f1915. Review.

PMID:
23442811
19.

Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).

Patti G, Pasceri V, D'Antonio L, D'Ambrosio A, Macrì M, Dicuonzo G, Colonna G, Montinaro A, Di Sciascio G.

Am J Cardiol. 2012 Aug 15;110(4):478-84. doi: 10.1016/j.amjcard.2012.04.017. Epub 2012 May 12.

PMID:
22583760
20.

Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention.

Deshpande NV, Pratiti R, Admane P, Mukherjee D, Mardikar HM.

Indian Heart J. 2012 Sep-Oct;64(5):444-8. doi: 10.1016/j.ihj.2012.07.022. Epub 2012 Jul 27.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk